Discovery of a diaminoquinoxaline benzenesulfonamide antagonist of HIV-1 Nef function using a yeast-based phenotypic screen

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Trible, Ronald P ^a   Narute, Purushottam ^a   Emert Sedlak, Lori A ^a   Alvarado, John J ^a   Atkins, Katelyn ^b   Thomas, Laurel ^a   Kodama, Toshiaki ^a   Yanamala, Naveena ^a   Korotchenko, Vasiliy ^c   Day, Billy W ^c   Thomas, Gary ^a   Smithgall, Thomas E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Hck; HIV 1; MHC I downregulation; Nef; Small molecule Nef antagonists; Src family kinases; Zap 70

Indexed keywords

4 CHLORO N [3 (2,3 DIHYDROBENZO[1,4]DIOXIN 6 YLAMINO)QUINOXALIN 2 YL]BENZENESULFONAMIDE; DAMINOZIDE; DLC 27 14; HEMATOPOIETIC CELL KINASE; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF HCK PROTEIN; NEF PROTEIN; PROTEIN INHIBITOR; RECOMBINANT NEF PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ANTIVIRAL ACTIVITY; ARTICLE; CELL CYCLE ARREST; CHIMERA; CONTROLLED STUDY; DOWN REGULATION; DRUG BINDING; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVATION; FLUOROMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DOCKING; NONHUMAN; PREDICTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE; VIRUS REPLICATION; YEAST CELL;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR DOCKING SIMULATION; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-HCK; QUINOXALINES; SACCHAROMYCES CEREVISIAE; SULFONAMIDES;

EID: 84887353252     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-135     Document Type: Article

References (67)

1. Fackler OT, Baur AS. Live and let die: Nef functions beyond HIV replication. Immunity 2002, 16:493-497. 10.1016/S1074-7613(02)00307-2, 11970873.
2. Geyer M, Fackler OT, Peterlin BM. Structure-function relationships in HIV-1 Nef. EMBO Rep 2001, 2:580-585. 10.1093/embo-reports/kve141, 1083955, 11463741.
3. Kestler HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991, 65:651-662. 10.1016/0092-8674(91)90097-I, 2032289.
4. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, Jolicoeur P. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998, 95:163-175. 10.1016/S0092-8674(00)81748-1, 9790524.
5. Hanna Z, Kay DG, Cool M, Jothy S, Rebai N, Jolicoeur P. Transgenic mice expressing human immunodeficiency virus type 1 in immune cells develop a severe AIDS-like disease. J Virol 1998, 72:121-132. 109356, 9420207.
6. Carl S, Greenough TC, Krumbiegel M, Greenberg M, Skowronski J, Sullivan JL, Kirchhoff F. Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol 2001, 75:3657-3665. 10.1128/JVI.75.8.3657-3665.2001, 114857, 11264355.
7. Kirchhoff F, Easterbrook PJ, Douglas N, Troop M, Greenough TC, Weber J, Carl S, Sullivan JL, Daniels RS. Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J Virol 1999, 73:5497-5508. 112607, 10364298.
8. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-991. 10.1126/science.270.5238.988, 7481804.
9. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995, 332:228-232. 10.1056/NEJM199501263320405, 7808489.
10. Zou W, Denton PW, Watkins RL, Krisko JF, Nochi T, Foster JL, Garcia JV. Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4 + CD8+ thymocytes. Retrovirology 2012, 9:44. 10.1186/1742-4690-9-44, 3403983, 22640559.
11. Malim MH, Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3:388-398. 10.1016/j.chom.2008.04.008, 18541215.
12. Foster JL, Garcia JV. HIV-1 Nef: at the crossroads. Retrovirology 2008, 5:84. 10.1186/1742-4690-5-84, 2563024, 18808677.
13. Saksela K. Interactions of the HIV/SIV pathogenicity factor Nef with SH3 domain-containing host cell proteins. Curr HIV Res 2011, 9:531-542. 10.2174/157016211798842107, 22103837.
14. Lee CH, Leung B, Lemmon MA, Zheng J, Cowburn D, Kuriyan J, Saksela K. A single amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein. EMBO J 1995, 14:5006-5015. 394604, 7588629.
15. Arold S, O'Brien R, Franken P, Strub MP, Hoh F, Dumas C, Ladbury JE. RT loop flexibility enhances the specificity of Src family SH3 domains for HIV-1 Nef. Biochemistry 1998, 37:14683-14691. 10.1021/bi980989q, 9778343.
16. Moarefi I, LaFevre-Bernt M, Sicheri F, Huse M, Lee C-H, Kuriyan J, Miller WT. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 1997, 385:650-653. 10.1038/385650a0, 9024665.
17. Briggs SD, Sharkey M, Stevenson M, Smithgall TE. SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1. J Biol Chem 1997, 272:17899-17902. 10.1074/jbc.272.29.17899, 9218412.
18. Briggs SD, Scholtz B, Jacque JM, Swingler S, Stevenson M, Smithgall TE. HIV-1 Nef promotes survival of myeloid cells by a Stat3-dependent pathway. J Biol Chem 2001, 276:25605-25611. 10.1074/jbc.M103244200, 11328823.
19. Komuro I, Yokota Y, Yasuda S, Iwamoto A, Kagawa KS. CSF-induced and HIV-1-mediated distinct regulation of Hck and C/EBPbeta represent a heterogeneous susceptibility of monocyte-derived macrophages to M-tropic HIV-1 infection. J Exp Med 2003, 198:443-453. 10.1084/jem.20022018, 2194092, 12900520.
20. Dikeakos JD, Atkins KM, Thomas L, Emert-Sedlak L, Byeon IJ, Jung J, Ahn J, Wortman MD, Kukull B, Saito M, Koizumi H, Williamson DM, Hiyoshi M, Barklis E, Takiguchi M, Suzu S, Gronenborn AM, Smithgall TE, Thomas G. Small molecule inhibition of HIV-1-induced MHC-I down-regulation identifies a temporally regulated switch in Nef action. Mol Biol Cell 2010, 21:3279-3292. 10.1091/mbc.E10-05-0470, 2947465, 20702582.
21. Atkins KM, Thomas L, Youker RT, Harriff MJ, Pissani F, You H, Thomas G. HIV-1 Nef binds PACS-2 to assemble a multikinase cascade that triggers major histocompatibility complex class I (MHC-I) down-regulation: analysis using short interfering RNA and knock-out mice. J Biol Chem 2008, 283:11772-11784. 10.1074/jbc.M707572200, 2431057, 18296443.
22. Hung CH, Thomas L, Ruby CE, Atkins KM, Morris NP, Knight ZA, Scholz I, Barklis E, Weinberg AD, Shokat KM, Thomas G. HIV-1 Nef assembles a Src family kinase-ZAP-70/Syk-PI3K cascade to downregulate cell-surface MHC-I. Cell Host Microbe 2007, 1:121-133. 10.1016/j.chom.2007.03.004, 18005690.
23. Hanna Z, Weng X, Kay DG, Poudrier J, Lowell C, Jolicoeur P. The pathogenicity of human immunodeficiency virus (HIV) type 1 Nef in CD4C/HIV transgenic mice is abolished by mutation of its SH3-binding domain, and disease development is delayed in the absence of Hck. J Virol 2001, 75:9378-9392. 10.1128/JVI.75.19.9378-9392.2001, 114506, 11533201.
24. Brugge JS, Jarosik G, Andersen J, Queral-Lustig A, Fedor-Chaiken M, Broach JR. Expression of Rous sarcoma virus transforming protein pp 60v-src in Saccharomyces cerevisiae cells. Mol Cell Biol 1987, 7:2180-2187. 365341, 3037349.
25. Kornbluth S, Jove R, Hanafusa H. Characterization of avian and viral p60src proteins expressed in yeast. Proc Natl Acad Sci U S A 1987, 84:4455-4459. 10.1073/pnas.84.13.4455, 305108, 2440023.
26. Murphy SM, Bergman M, Morgan DO. Suppression of c-Src activity by C-terminal Src kinase involves the c-Src SH2 and SH3 domains: analysis with Saccharomyces cerevisiae. Mol Cell Biol 1993, 13:5290-5300. 360223, 7689149.
27. Florio M, Wilson LK, Trager JB, Thorner J, Martin GS. Aberrant protein phosphorylation at tyrosine is responsible for the growth-inhibitory action of pp 60v-src expressed in the yeast Saccharomyces cerevisiae. Mol Biol Cell 1994, 5:283-296. 10.1091/mbc.5.3.283, 301037, 8049521.
28. Nada S, Okada M, MacAuley A, Cooper JA, Nakagawa H. Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src. Nature 1991, 351:69-72. 10.1038/351069a0, 1709258.
29. Trible RP, Emert-Sedlak L, Smithgall TE. HIV-1 Nef selectively activates SRC family kinases HCK, LYN, and c-SRC through direct SH3 domain interaction. J Biol Chem 2006, 281:27029-27038. 10.1074/jbc.M601128200, 2892265, 16849330.
30. Nada S, Yagi T, Takeda H, Tokunaga T, Nakagawa H, Ikawa Y, Okada M, Aizawa S. Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell 1993, 73:1125-1135. 10.1016/0092-8674(93)90642-4, 8513497.
31. Superti-Furga G, Fumagalli S, Koegl M, Courtneidge SA, Draetta G. Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. EMBO J 1993, 12:2625-2634. 413509, 7687537.
32. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999, 3:639-648. 10.1016/S1097-2765(00)80357-3, 10360180.
33. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997, 385:602-609. 10.1038/385602a0, 9024658.
34. Engen JR, Wales TE, Hochrein JM, Meyn MA, Banu OS, Bahar I, Smithgall TE. Structure and dynamic regulation of Src-family kinases. Cell Mol Life Sci 2008, 65:3058-3073. 10.1007/s00018-008-8122-2, 18563293.
35. Lee C-H, Saksela K, Mirza UA, Chait BT, Kuriyan J. Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell 1996, 85:931-942. 10.1016/S0092-8674(00)81276-3, 8681387.
36. Choi HJ, Smithgall TE. Conserved residues in the HIV-1 Nef hydrophobic pocket are essential for recruitment and activation of the Hck tyrosine kinase. J Mol Biol 2004, 343:1255-1268. 10.1016/j.jmb.2004.09.015, 15491611.
37. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002, 21:8075-8088. 10.1038/sj.onc.1206008, 12444544.
38. Meyn MA, Schreiner SJ, Dumitrescu TP, Nau GJ, Smithgall TE. SRC family kinase activity is required for murine embryonic stem cell growth and differentiation. Mol Pharmacol 2005, 68:1320-1330. 10.1124/mol.104.010231, 15985613.
39. Meyn MA, Smithgall TE. Chemical genetics identifies c-Src as an activator of primitive ectoderm formation in murine embryonic stem cells. Sci Signal 2009, 2:ra64. 2775445, 19825829.
40. Emert-Sedlak L, Kodama T, Lerner EC, Dai W, Foster C, Day BW, Lazo JS, Smithgall TE. Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. ACS Chem Biol 2009, 4:939-947. 10.1021/cb900195c, 2861989, 19807124.
41. Narute PS, Smithgall TE. Nef alleles from all major HIV-1 clades activate Src-family kinases and enhance HIV-1 replication in an inhibitor-sensitive manner. PLoS One 2012, 7:e32561. 10.1371/journal.pone.0032561, 3290594, 22393415.
42. Blagoveshchenskaya AD, Thomas L, Feliciangeli SF, Hung CH, Thomas G. HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell 2002, 111:853-866. 10.1016/S0092-8674(02)01162-5, 12526811.
43. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998, 391:397-401. 10.1038/34929, 9450757.
44. Dikeakos JD, Thomas L, Kwon G, Elferich J, Shinde U, Thomas G. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I. Mol Biol Cell 2012, 23:2184-2197. 10.1091/mbc.E11-11-0928, 3364181, 22496420.
45. Emert-Sedlak LA, Narute P, Shu ST, Poe JA, Shi H, Yanamala N, Alvarado JJ, Lazo JS, Yeh JI, Johnston PA, Smithgall TE. Effector Kinase Coupling Enables High-Throughput Screens for Direct HIV-1 Nef Antagonists with Antiretroviral Activity. Chem Biol 2013, 20:82-91. 10.1016/j.chembiol.2012.11.005, 23352142.
46. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, De Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006, 49:6819-6832. 10.1021/jm060727j, 17154512.
47. Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, Nakashima K, Ishimori M, Nagai H, Li YF, Yura T, Bacon KB. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 2003, 306:1174-1181. 10.1124/jpet.103.052316, 12766258.
48. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010, 31:455-461. 3041641, 19499576.
49. Liu LX, Heveker N, Fackler OT, Arold S, Le Gall S, Janvier K, Peterlin BM, Dumas C, Schwartz O, Benichou S, Benarous R. Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions. J Virol 2000, 74:5310-5319. 10.1128/JVI.74.11.5310-5319.2000, 110886, 10799608.
50. Jia X, Singh R, Homann S, Yang H, Guatelli J, Xiong Y. Structural basis of evasion of cellular adaptive immunity by HIV-1 Nef. Nat Struct Mol Biol 2012, 19:701-706. 10.1038/nsmb.2328, 3407041, 22705789.
51. Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2007, 2:2212-2221. 10.1038/nprot.2007.321, 17853878.
52. Vedadi M, Niesen FH, Allali-Hassani A, Fedorov OY, Finerty PJ, Wasney GA, Yeung R, Arrowsmith C, Ball LJ, Berglund H, Hui R, Marsden BD, Nordlund P, Sundstrom M, Weigelt J, Edwards AM. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci U S A 2006, 103:15835-15840. 10.1073/pnas.0605224103, 1595307, 17035505.
53. Smithgall TE, Thomas G. Small molecule inhibitors of the HIV-1 virulence factor, Nef. Drug Discov Today: Technol 2013, 10:e523-e529.
54. Lugari A, Breuer S, Coursindel T, Opi S, Restouin A, Shi X, Nazabal A, Torbett BE, Martinez J, Collette Y, Parrot I, Arold ST, Morelli X. A specific protein disorder catalyzer of HIV-1 Nef. Bioorg Med Chem 2011, 19:7401-7406. 10.1016/j.bmc.2011.10.051, 22061824.
55. Betzi S, Restouin A, Opi S, Arold ST, Parrot I, Guerlesquin F, Morelli X, Collette Y. Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein. Proc Natl Acad Sci U S A 2007, 104:19256-19261. 10.1073/pnas.0707130104, 2148277, 18042718.
56. Gervaix A, West D, Leoni LM, Richman DD, Wong-Staal F, Corbeil J. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci U S A 1997, 94:4653-4658. 10.1073/pnas.94.9.4653, 20779, 9114046.
57. Friedrich TC, Piaskowski SM, Leon EJ, Furlott JR, Maness NJ, Weisgrau KL, Mac Nair CE, Weiler AM, Loffredo JT, Reynolds MR, Williams KY, Klimentidis YC, Wilson NA, Allison DB, Rakasz EG. High viremia is associated with high levels of in vivo major histocompatibility complex class I Downregulation in rhesus macaques infected with simian immunodeficiency virus SIVmac239. J Virol 2010, 84:5443-5447. 10.1128/JVI.02452-09, 2863841, 20219903.
58. Sol-Foulon N, Sourisseau M, Porrot F, Thoulouze MI, Trouillet C, Nobile C, Blanchet F, DiB V, Noraz N, Taylor N, Alcover A, Hivroz C, Schwartz O. ZAP-70 kinase regulates HIV cell-to-cell spread and virological synapse formation. EMBO J 2007, 26:516-526. 10.1038/sj.emboj.7601509, 1783460, 17215865.
59. Simmons A, Aluvihare V, McMichael A. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 2001, 14:763-777. 10.1016/S1074-7613(01)00158-3, 11420046.
60. Yanagi S, Inatome R, Takano T, Yamamura H. Syk expression and novel function in a wide variety of tissues. Biochem Biophys Res Commun 2001, 288:495-498. 10.1006/bbrc.2001.5788, 11676469.
61. Chutiwitoonchai N, Hiyoshi M, Mwimanzi P, Ueno T, Adachi A, Ode H, Sato H, Fackler OT, Okada S, Suzu S. The identification of a small molecule compound that reduces HIV-1 Nef-mediated viral infectivity enhancement. PLoS One 2011, 6:e27696. 10.1371/journal.pone.0027696, 3217016, 22110726.
62. Temesgen Z, Warnke D, Kasten MJ. Current status of antiretroviral therapy. Expert Opin Pharmacother 2006, 7:1541-1554. 10.1517/14656566.7.12.1541, 16872258.
63. Machouf N, Thomas R, Nguyen VK, Trottier B, Boulassel MR, Wainberg MA, Routy JP. Effects of drug resistance on viral load in patients failing antiretroviral therapy. J Med Virol 2006, 78:608-613. 10.1002/jmv.20582, 16555280.
64. Turner D, Wainberg MA. HIV transmission and primary drug resistance. AIDS Rev 2006, 8:17-23.
65. Lerner EC, Smithgall TE. SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo. Nat Struct Biol 2002, 9:365-369.
66. Kushnirov VV. Rapid and reliable protein extraction from yeast. Yeast 2000, 16:857-860. 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B, 10861908.
67. Sanner MF. Python: a programming language for software integration and development. J Mol Graph Model 1999, 17:57-61.